Evidence map›Paper›PMID 40453139›Full record

ArticleBlood neoplasia2025

Driver mutations in myeloid and lymphoid cells point to multipotent progenitor origin of diverse histiocytic neoplasms.

Astrid G S van Halteren, Paul G Kemps, Jelske Forma-Borst, Yanling Xiao, Maud A J I van den Oetelaar, Nina U Gelineau, Robert M Verdijk, Lydia E Vos, Koen D Quint, Cor van den Bos and 2 more

Abstract read
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Astrid G S van HalterenClinical Immunology and Allergology Section, Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Paul G KempsPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Jelske Forma-BorstDepartment of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
Yanling XiaoDepartment of Immunology, Leiden University Medical Center, Leiden, The Netherlands.
Maud A J I van den OetelaarDepartment of Immunology, Laboratory Medical Immunology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Nina U GelineauPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Robert M VerdijkDepartment of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
Lydia E VosDepartment of Dermatology, Haaglanden Medical Center, The Hague, The Netherlands.
Koen D QuintDepartment of Dermatology, Leiden University Medical Center, Leiden, The Netherlands.
Cor van den BosPrincess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
Jan A M van LaarClinical Immunology and Allergology Section, Department of Internal Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Molecular Pathogenesis and Therapy of Systemic Histiocytic NeoplasmsR37CA259260 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eli Lous Diamond · 2021 to 2026
$3.3M
NCI NIH HHS P30 CA008748NCI NIH HHS R37 CA259260
6 · The paper itself

Abstract

Histiocytic neoplasms are rare myeloid diseases characterized by MAPK pathway-activating genetic alterations. We investigated their hematopoietic origin, with a focus on non-Langerhans cell histiocytoses. Using droplet digital polymerase chain reaction assays specific for

Identifiers

PMID40453139
PMCPMC12067900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.